The development of New Delhi metallo-β-lactamase-1 inhibitors since 2018

Microbiol Res. 2022 Aug:261:127079. doi: 10.1016/j.micres.2022.127079. Epub 2022 May 27.

Abstract

New Delhi metallo-β-lactamase-1 (NDM-1) can hydrolyze almost all antibiotics of the β-lactam group, resulting in the generation of multidrug resistant bacteria. Besides its broad hydrolytic activity, pathogens expressing NDM-1 often harbor other antibiotic-resistant genes, further promoting the pervasion of multi-resistant clinical isolates and making clinically available drugs scantier. Despite the urgent need for NDM-1 inhibitors, there is no approved drug in clinic. Here, we summarize NDM-1 inhibitors developed since 2018, classify these compounds by chemical scaffolds, and propose some inconsistencies and notable problems among these studies, which are expected to benefit future research.

Keywords: Antimicrobial resistance; NDM-1 inhibitors; New Delhi metallo-β-lactamase-1.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Drug Resistance, Multiple, Bacterial* / genetics
  • Microbial Sensitivity Tests
  • beta-Lactamases* / chemistry
  • beta-Lactamases* / genetics

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases
  • beta-lactamase NDM-1